Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 6.4% – Time to Buy?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares shot up 6.4% on Wednesday . The stock traded as high as $14.60 and last traded at $14.26. Approximately 144,177 shares traded hands during trading, a decline of 43% from the average daily volume of 254,397 shares. The stock had previously closed at $13.40.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LYEL. Citizens Jmp reissued a “market outperform” rating and issued a $34.00 price objective on shares of Lyell Immunopharma in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Lyell Immunopharma has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Lyell Immunopharma Stock Down 2.4%

The stock’s 50-day simple moving average is $14.87 and its two-hundred day simple moving average is $20.49. The company has a market capitalization of $332.10 million, a price-to-earnings ratio of -0.98 and a beta of -0.06.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The business had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, sell-side analysts forecast that Lyell Immunopharma, Inc. will post -7.87 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. BBR Partners LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at about $210,000. ExodusPoint Capital Management LP purchased a new position in Lyell Immunopharma during the fourth quarter worth approximately $262,000. Marshall Wace LLP acquired a new position in Lyell Immunopharma during the second quarter worth $94,000. Jane Street Group LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth $382,000. Finally, Barclays PLC increased its stake in shares of Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares during the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.